A recent study by Tanaka et al. (2025) explores the use of E6011, an anti-human fractalkine monoclonal antibody, in treating primary biliary cholangitis (PBC). The study highlights the need for new treatments beyond the current first-line therapy, ursodeoxycholic acid (UDCA), due to the autoimmune nature of PBC.
The focus on developing new therapies like E6011 indicates a push towards more effective management options for PBC. While UDCA remains the standard treatment, there is a growing interest in exploring additional therapies to improve patient outcomes. This research suggests that there is ongoing effort to find better solutions for managing PBC, which could potentially lead to improved treatment options in the future.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
